Paradigm Biopharmaceuticals (ASX: PAR)

Company Profile– Founded in 2014, Paradigm Biopharmaceuticals (ASX: PAR) is an Australian biopharmaceutical company which is involved in the research and development of therapeutic products for human use and it is focused on repurposing the drug pentosan polysulphate sodium to treat inflammation. Mr. Paul Rennie is the Managing Director of the company. The company is 517 Flinders Lane Level 2 Melbourne, VIC 3000, Australia.

Facebook Comments

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.

6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report


Please enter your comment!
Please enter your name here